Enfermedades gastrointestinales y hepáticas

Foto de Enfermedades gastrointestinales y hepáticas

Foto de Université Denis Diderot

Université Denis Diderot

París, Francia

Publicaciones en colaboración con investigadores/as de Université Denis Diderot (4)

2019

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170

2018

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 1, pp. e23-e34
Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study
Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832

2016

Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663